Sign in to view content

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)

Chirag D. Jhaveri, MD, FASRS

Video
Published 2021

Related

What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020
Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option
Mohsin H. Ali, MD
Updates from the Field
2025

Category: AMD-Neovascular

See more